DNA demethylation and cancer metastasis: therapeutic implications. 2008

Moshe Szyf
McGill University, Department of Pharmacology and Therapeutics, 3655 Sir William Osler Promenade, Montreal PQ, H3G 1Y6, Canada +1 514 398 7107 ; +1 514 398 6690 ; moshe.szyf@mcgill.ca.

BACKGROUND DNA methylation is a covalent modification of DNA, which plays a critical role in regulation of gene expression. Methyl marks in critical regulatory regions of genes silence gene expression. Two contrasting changes in DNA methylation were documented in cancers: regional hypermethylation of tumor suppressor genes and global hypomethylation. OBJECTIVE Most of the attention in the field has been directed toward the phenomenon of hypermethylation and silencing of tumor suppressor genes. Hypermethylation indeed plays an extremely important role in cancer and cancer progression. Nevertheless, hypomethylation is emerging now as a mechanism that might lead to activation of prometastatic genes in cancer. CONCLUSIONS Both methylation and demethylation could be pharmacologically modulated. It is argued here that inhibition of hypomethylation might provide a new therapeutic approach to antimetastatic therapy.

UI MeSH Term Description Entries

Related Publications

Moshe Szyf
June 2022, International journal of molecular sciences,
Moshe Szyf
March 2023, Expert reviews in molecular medicine,
Moshe Szyf
September 2016, Pakistan journal of pharmaceutical sciences,
Moshe Szyf
June 1986, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
Moshe Szyf
January 2007, Clinical & experimental metastasis,
Copied contents to your clipboard!